|Dr. Robert T. Foster B.Sc., BSc (Pharm), Pharm.D., Ph.D.||Pres, CEO & Director||600k||N/A||1958|
|Mr. John T. Cavan||Chief Financial Officer||406.25k||N/A||1958|
|Dr. Daren Ure Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Sharen Pyatetskaya||Director of Investor Relations||N/A||N/A||N/A|
|Dr. Daniel Trepanier Ph.D.||Sr. VP of Drug Devel.||N/A||N/A||N/A|
|Dr. Patrick Mayo Ph.D.||Sr. VP of Clinical Pharmacology||N/A||N/A||N/A|
|Dr. Todd M. Hobbs M.D.||Chief Medical Officer||N/A||N/A||N/A|
|Dr. John Z. Sullivan-Bolyai||Part-Time Consultant||N/A||N/A||1948|
|Dr. Stephen A. Harrison||Member of Scientific Advisory Board & Consultant Medical Director||N/A||N/A||N/A|
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Hepion Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.